Page last updated: 2024-08-21

pyrazines and Muscular Diseases

pyrazines has been researched along with Muscular Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Abouhajar, A; Alcock, L; Bigirumurame, T; Bradley, P; Brown, L; Campbell, I; Del Din, S; Faitg, J; Falkous, G; Gorman, GS; Lakey, R; McFarland, R; Newman, J; Rochester, L; Ryan, V; Smith, H; Steel, A; Stefanetti, RJ; Su, H; Taylor, RW; Thomas, NJP; Tuppen, H; Vincent, AE; Warren, C; Watson, G	1
Ge, Q; Jiang, S; Li, X; Liu, Y	1
Isayama, R; Mizutani, R; Nakagawa, M; Shiga, K; Shimazaki, C; Tokuda, T	1

Trials

1 trial(s) available for pyrazines and Muscular Diseases

Article	Year
Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. Trials, 2022, Sep-20, Volume: 23, Issue:1 Topics: Adenosine Triphosphate; Adult; Aspirin; Child; Fatigue; Humans; Mitochondrial Myopathies; Muscular Diseases; Pyrazines; Quality of Life; Randomized Controlled Trials as Topic	2022

Article

Year

Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy.

Trials, 2022, Sep-20, Volume: 23, Issue:1

Topics: Adenosine Triphosphate; Adult; Aspirin; Child; Fatigue; Humans; Mitochondrial Myopathies; Muscular Diseases; Pyrazines; Quality of Life; Randomized Controlled Trials as Topic

2022

Other Studies

2 other study(ies) available for pyrazines and Muscular Diseases

Article	Year
Tetramethylpyrazine protects against high glucose-induced vascular smooth muscle cell injury through inhibiting the phosphorylation of JNK, p38MAPK, and ERK. The Journal of international medical research, 2018, Volume: 46, Issue:8 Topics: Animals; Aorta, Thoracic; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Glucose; Hyperglycemia; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Muscular Diseases; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Rats; Signal Transduction; Vascular Diseases; Vasodilator Agents	2018
Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib. Journal of neurology, 2010, Volume: 257, Issue:12 Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Muscular Diseases; Plaque, Amyloid; Protease Inhibitors; Pyrazines	2010

Article

Year

Tetramethylpyrazine protects against high glucose-induced vascular smooth muscle cell injury through inhibiting the phosphorylation of JNK, p38MAPK, and ERK.

The Journal of international medical research, 2018, Volume: 46, Issue:8

Topics: Animals; Aorta, Thoracic; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Glucose; Hyperglycemia; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Muscular Diseases; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Rats; Signal Transduction; Vascular Diseases; Vasodilator Agents

2018

Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.

Journal of neurology, 2010, Volume: 257, Issue:12

Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Muscular Diseases; Plaque, Amyloid; Protease Inhibitors; Pyrazines

2010